ZOLL LifeVest Prescribed by Physicians at All U.S. News and World Report “Honor Roll” Hospitals and All 50 “Best Cardiolog

Milestone Result for Fourth Consecutive Year

CHELMSFORD, Mass.--(BUSINESS WIRE)-- ZOLL Medical Corporation (NASDAQ GS: ZOLL), a manufacturer of medical devices and related software solutions, today announced that physicians at all of the 17 “Honor Roll” hospitals and all of the 50 “Best Cardiology and Heart Surgery” hospitals designated by U.S. News and World Report for 2011-2012 have prescribed the ZOLL LifeVest® Wearable Defibrillator for patients.

The LifeVest is worn by patients at risk for sudden cardiac arrest (SCA), providing protection during their changing condition and while permanent SCA risk has not been established. The LifeVest allows a patient’s physician time to assess their long-term arrhythmic risk and make appropriate plans. The LifeVest is lightweight and easy to wear, allowing patients to return to their activities of daily living, while having the peace of mind that they are protected from SCA. The LifeVest does not require bystander intervention and has a 98 percent first treatment shock success rate for resuscitating patients with SCA.

“For the fourth year in a row, physicians at all of the ‘Honor Roll’ and ‘Best Cardiology and Heart Surgery’ hospitals have prescribed the LifeVest to protect their patients from sudden cardiac death,” said Richard A. Packer, Chief Executive Officer of ZOLL. “The fact that physicians at all of these premier institutions prescribe the LifeVest is a testament to the important role this treatment option plays in the standard of care for patients at risk of SCA.”

The LifeVest is used for a wide range of patient conditions, including following a heart attack, before or after bypass surgery or stent placement, as well as cardiomyopathy or congestive heart failure, that place patients at particular risk. To date, the LifeVest has been prescribed to more than 45,000 patients. For more information, go to www.zoll.com or 1.800.543.3267.

U.S. News and World Report’s “Best Hospitals” is an annual ranking of the country’s elite medical centers that assesses how well a hospital handles complex and demanding situations. From among the 4,825 hospitals considered for the report, only 140 were ranked in one or more of the 16 specialties, and from those, only 17 qualified for the “Honor Roll” designation by earning high scores in at least six specialties. U.S. News and World Report also named the 50 “Best Cardiology and Heart Surgery” hospitals for 2011-2012 based on rankings within the specific category.

About ZOLL Medical Corporation

ZOLL Medical Corporation develops and markets medical devices and related software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care.

A NASDAQ Global Select company and a Forbes 100 Most Trustworthy Company for the past three years, ZOLL develops and manufactures its products in the United States, in California, Colorado, Illinois, Massachusetts, Pennsylvania, and Rhode Island. More than 400 direct sales and service representatives, 1,100 business partners, and 200 independent representatives serve our customers in over 140 countries around the globe. For more information, visit www.zoll.com.

Certain statements contained in this press release, including statements regarding the anticipated development of the Company's business, our belief regarding revenues, and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the Company's Annual Report on Form 10-K filed with the SEC on December 17, 2010 and updated in the Company’s Quarterly Reports on Form 10-Q filed subsequently to the Form 10-K, including the Form 10-Q Quarterly Report filed on August 8, 2011. You should not place undue reliance on the forward-looking statements in this press release, and the Company disavows any obligation to update or supplement those statements in the event of any changes in the facts, circumstances, or expectations that underlie those statements.

Copyright © 2011 ZOLL Medical Corporation. All rights reserved. LifeVest and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries. All product names are the property of their respective owners.



CONTACT:

Investor Contact:
ZOLL Medical Corporation
A. Ernest Whiton, +1-978-421-9655
Chief Financial Officer
or
Media Contact:
ZOLL Medical Corporation
Diane Egan, +1 978-421-9637
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Hospitals  Medical Devices  Medical Supplies  General Health

MEDIA:

Logo
 Logo

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.